Grapiprant, sold under the brand name Galliprant in some regions, is a prescription pain medicine used for osteoarthritis in dogs. It belongs to a newer class called piprants and works differently from traditional NSAIDs by selectively blocking the prostaglandin E2 EP4 receptor, a receptor strongly involved in osteoarthritis pain and inflammation. That targeted mechanism can make it attractive for selected dogs, but it should not be treated as risk-free or automatically safer for every patient.
Dog Medication Math Calculator
Enter your dog’s current body weight, then use only the dose already provided by your veterinarian or pharmacy label. The calculator converts lb/kg and can work out mg and liquid mL. It does not choose or recommend a dose.
Dose information from your veterinarian
Optional liquid conversion

This guide explains how grapiprant differs from carprofen, meloxicam and coxib NSAIDs, what side effects owners may see, why GI monitoring still matters, how age and organ disease influence selection, why combining it with other anti-inflammatory drugs can be risky, and what owners should track to know whether treatment is actually helping.
What grapiprant is
Grapiprant is an EP4 prostaglandin receptor antagonist used to control pain associated with canine osteoarthritis.
Why it is called a piprant
Piprants act at specific prostaglandin receptors rather than broadly inhibiting cyclooxygenase enzymes that produce prostaglandins.
How the EP4 receptor relates to arthritis pain
Prostaglandin E2 acting through EP4 contributes to pain sensitization and inflammation within arthritic joints.
Why this mechanism is different from traditional NSAIDs
Traditional NSAIDs reduce prostaglandin synthesis upstream, while grapiprant blocks one selected receptor pathway downstream.
Why targeted does not mean side-effect free
EP4 signaling also has physiologic roles, and GI adverse effects can still occur.
Why grapiprant is used for osteoarthritis
Its approved role centers on chronic osteoarthritis pain rather than every type of acute injury or post-operative pain.
Why arthritis treatment is more than medication
Weight control, exercise, rehabilitation, muscle maintenance and home adaptation remain essential. See Arthritis in Dogs.
Why grapiprant is not a sedative
Pain relief should improve mobility without making the dog sleepy simply because the medication is working.
How grapiprant differs from carprofen
Carprofen inhibits cyclooxygenase activity, while grapiprant targets the EP4 receptor. Their milligram doses cannot be compared directly.
How it differs from meloxicam
Meloxicam is a traditional NSAID with COX preference, while grapiprant acts downstream at a receptor.
How it differs from firocoxib or deracoxib
Coxibs preferentially inhibit COX-2; grapiprant does not inhibit COX enzymes in the same way.
Why these mechanistic differences do not create a simple safety ranking
Patient age, organ function, GI history and individual response still determine whether a given drug is appropriate.
Galliprant dosage by weight: current FDA-labeled regimen
The current U.S. Galliprant label gives a dose of 2 mg/kg (0.9 mg/lb) by mouth once daily for control of pain and inflammation associated with osteoarthritis in dogs. The label uses tablet-strength bands, and dogs under 8 lb (3.6 kg) cannot be accurately dosed with the available tablet sizes.
| Dog weight | Label tablet amount | Reader takeaway |
|---|---|---|
| 8–15 lb | ½ of a 20 mg tablet | Weight bands are part of the official label |
| 15.1–30 lb | 1 × 20 mg tablet | Use the prescribed tablet strength, not a homemade conversion |
| 30.1–45 lb | ½ of a 60 mg tablet | Only scored tablets should be split as intended |
| 45.1–75 lb | 1 × 60 mg tablet | Monitor GI tolerance and overall response |
| 75.1–150 lb | 1 × 100 mg tablet | The lowest effective dose for the shortest appropriate duration is still the goal |
Source: the current FDA Galliprant client information and dosing label. The table explains the label; it does not determine whether grapiprant is the right arthritis medicine for a particular dog.
Why DogMedsHub does not provide an autonomous dose calculator
Weight alone cannot determine whether grapiprant is appropriate or whether another analgesic is safer.
Why current body weight matters
Veterinary dosing depends on accurate weight and labeled tablet strengths.
How grapiprant is usually given
It is commonly provided as veterinary tablets in weight-based strengths according to product labeling.
Why food instructions matter
Product labels may specify how food affects absorption, so owners should follow the exact directions for the prescribed formulation.
Why changing meal timing can alter exposure
Food can affect drug absorption, making consistent administration important.
Common adverse effects
Vomiting, diarrhea, soft stool, appetite changes and lethargy can occur.
Why vomiting still matters even with a targeted receptor drug
Repeated vomiting can lead to dehydration and may indicate poor tolerance or another disease.
Why diarrhea still matters
Persistent stool changes can reduce hydration and quality of life and should not be dismissed simply because the drug is not a traditional NSAID.
Why appetite loss matters
Reduced intake can be an early sign that treatment is not being tolerated well.
Why black stool is still a red flag
GI bleeding is not a routine expected effect and requires prompt veterinary assessment.
Why kidney function still belongs in the safety discussion
Although grapiprant’s mechanism differs from COX inhibitors, dogs with kidney disease are medically fragile and require individualized treatment choices.
Why liver disease matters
Hepatic handling and concurrent disease can influence overall exposure and tolerance.
Why senior dogs often have several competing risks
Arthritis, kidney disease, heart disease, GI disease and polypharmacy commonly coexist.
Why a “gentler” reputation can create false reassurance
Owners may assume monitoring is unnecessary, but adverse effects and disease interactions still matter.
Why baseline bloodwork may still be useful
It provides context in senior or medically complex dogs and can identify organ disease that changes the overall pain plan.
Why ongoing monitoring remains reasonable
Long-term analgesic use should be reviewed for both benefit and tolerability.
Why grapiprant should not be combined casually with another NSAID
Overlapping prostaglandin-pathway effects can increase adverse-event risk even though the mechanisms are not identical.
Why prednisone should not be added casually
Corticosteroids can increase GI risk and complicate inflammatory treatment plans.
Why aspirin should be disclosed
Recent aspirin use affects GI and platelet risk and can complicate transitions.
Why ibuprofen and naproxen remain dangerous
Human NSAID exposure can cause severe poisoning regardless of whether the dog is taking grapiprant.
Why washout planning still matters
Switching from a traditional NSAID or corticosteroid to grapiprant may require a transition period based on the previous drug and patient risk.
Why there is no universal internet washout rule
The safe interval depends on pharmacology, duration, GI history and urgency.
Why non-NSAID bridges may be useful
Gabapentin, amantadine, opioids or rehabilitation can support comfort while a risky overlap is avoided.
Why gabapentin may be combined with grapiprant
They act through different pain pathways and may be used together in multimodal management when appropriate.
Why additive sedation is less of a direct concern from grapiprant itself
Grapiprant is not a sedative, though concurrent gabapentin or other CNS-active drugs can still cause drowsiness.
Why pain relief should be judged by function
Track rising, stairs, walking, sleep, play and willingness to engage with family activities.
Why a dog may still need rehabilitation
Medication does not rebuild muscle or restore balance lost through months of reduced activity.
Why weight control can be one of the strongest interventions
Reducing excess body fat lowers joint load and can improve mobility without increasing medication exposure.
Why body condition score matters more than scale weight alone
Muscle and fat distribution influence joint stress and mobility.
Why sudden pain worsening needs examination
A new ligament injury, spinal disease or fracture should not be treated by simply increasing analgesics.
Why one painful joint can hide another
Dogs compensate and shift weight, so full orthopedic assessment matters when function changes.
Why cancer can mimic osteoarthritis
Persistent focal lameness or bone pain in older dogs deserves diagnostic imaging.
Why the medication may seem less effective over time
Disease progression, weight gain, new injury or loss of muscle can reduce apparent benefit.
Why dose escalation is not always appropriate
Reassessment may identify a different cause of pain or the need for multimodal therapy.
Why owner diaries help
Weekly notes on mobility and comfort provide a better trend than memory alone.
Why videos help
Short clips of rising, walking and using stairs can show changes that are hard to reproduce in the clinic.
Why quality of life should guide long-term decisions
Comfort, sleep, appetite, interaction and ability to enjoy normal activities matter as much as a numerical pain score.
What if a dose is missed?
Do not automatically double. See Missed Dose.
What if an extra dose is given?
Contact the veterinarian with the exact strength and timing. See Double Dose.
Why flavored tablets need secure storage
Palatable veterinary medication can be eaten in large amounts if left accessible.
Why original packaging matters
It helps emergency clinicians identify the exact product and strength after accidental ingestion.
When to call the veterinarian
Repeated vomiting, diarrhea, appetite loss, unusual lethargy or worsening mobility deserves review.
When urgent care is appropriate
Collapse, blood in vomit, black stool, severe weakness or suspected major overdose requires prompt assessment.
What owners should track
- dose and time;
- food timing;
- appetite;
- vomiting or diarrhea;
- stool color;
- mobility and pain;
- other NSAIDs or steroids;
- recent illness or dehydration.
How this page fits DogMedsHub
This is the main medication page for grapiprant/Galliprant. Class-level safety remains on NSAID Safety for Dogs, while arthritis context remains on Arthritis in Dogs.
The FDA’s pain-reliever guidance for pets supports veterinarian-directed analgesic use, attention to side effects and avoidance of unsafe anti-inflammatory combinations.
Why grapiprant is sometimes considered for dogs that need a different anti-inflammatory approach
Its EP4-receptor mechanism may be attractive when a veterinarian wants osteoarthritis analgesia without traditional COX inhibition, but this should not be interpreted as permission to ignore GI signs or organ disease.
Why a dog that had an NSAID adverse event still needs a careful discussion
Previous ulceration, kidney injury or severe vomiting means the overall risk profile is higher, regardless of whether the next drug uses a different pathway.
Why prior steroid use still matters
Recent prednisone or depot steroid exposure can complicate any transition to an anti-inflammatory analgesic.
Why the timing of a switch should be individualized
A dog leaving long-term meloxicam and a dog that received one dose of carprofen are not equivalent transition cases.
Why the product should be given consistently
Food timing can influence absorption, so changing between fed and fasted administration from day to day may produce less predictable exposure.
Why owners should read the veterinary label rather than internet routines
Brand formulations and regional labeling can differ, and the veterinarian may have chosen a specific schedule for that dog.
Why GI signs should be documented from baseline
Some senior dogs already have intermittent soft stool or appetite variation. Knowing what was present before treatment helps identify new adverse effects.
Why vomiting after the first few doses matters
Early repeated vomiting can show poor tolerance and may warrant a different analgesic rather than simply pushing through.
Why chronic mild diarrhea still matters
Even when not dramatic, persistent stool changes can reduce hydration and quality of life during long-term therapy.
Why body weight is part of both safety and effectiveness
Weight affects dosing, but excess body fat also increases joint load and can make pain harder to control.
Why muscle mass matters
A thin senior dog can weigh less while also having worse weakness, so scale weight alone does not describe mobility health.
Why a rehabilitation plan can reveal whether pain control is adequate
If the dog cannot perform gentle strengthening despite medication, pain may still be poorly controlled or another problem may be present.
Why a drug can help pain without reversing stiffness immediately
Longstanding muscle contracture and reduced range of motion take time to improve even when joint pain decreases.
Why sleep quality is a useful outcome
Dogs with chronic arthritis often shift position, pant or wake at night. Better uninterrupted rest can signal meaningful pain improvement.
Why reluctance to jump is not always a failure
Some activities remain mechanically difficult even when pain is improved, especially in large or elderly dogs.
Why owner expectations should be realistic
The goal is improved comfort and function, not turning a senior arthritic dog back into a puppy.
Why medication should not encourage unsafe overactivity
Dogs that suddenly feel better may run or jump before muscles and joints are conditioned, leading to a flare or new injury.
Why a gradual exercise increase is safer
Small increases in duration or difficulty allow muscle and connective tissue to adapt.
Why intermittent “bad days” deserve context
Weather, long walks or minor slips can produce temporary flares that do not automatically require a medication change.
Why repeated bad days deserve reassessment
Progressive decline may indicate worsening arthritis, a new orthopedic injury or another painful condition.
Why a dog on grapiprant can still need gabapentin
Neuropathic or central-sensitization pain can coexist with joint inflammation, and a different analgesic pathway may add benefit.
Why combining medications should have a purpose
Every added drug should target a defined problem rather than simply increase the total number of pain medicines.
Why CBD and supplements should be disclosed
They can add GI or sedative effects and make it harder to know which component of the plan is helping.
Why long-term treatment should include medication reconciliation
New prescriptions from emergency or specialty clinics can create interaction risk if the existing arthritis medication is not documented.
Why pet sitters need the exact plan
They should know that another NSAID or prednisone must not be added for a perceived pain flare.
Why a mobility crisis should not be solved by extra tablets
Sudden inability to stand or bear weight can signal a new injury or neurologic problem and needs examination.
Why urination and drinking are still useful monitoring points
Changes may reveal kidney disease, endocrine disease or another health problem that changes the broader pain plan.
Why senior-dog rechecks should be whole-patient reviews
Arthritis treatment must account for heart, kidney, liver, GI and cognitive health as those conditions evolve.
Why the best analgesic can change over time
A drug chosen for a relatively healthy older dog may no longer be the best option after organ disease or recurrent GI problems develop.
Why stopping an ineffective drug is part of good care
Long-term medication should earn its place through measurable benefit and acceptable tolerability.
Why grapiprant should still be documented as an anti-inflammatory pain medicine
Because it is not a traditional COX-inhibiting NSAID, owners may forget to mention it when another clinician asks about anti-inflammatory drugs. That omission can lead to unsafe stacking with another pain medicine or a corticosteroid.
Why emergency and specialty clinics need the last-dose time
Knowing when grapiprant was last given helps clinicians plan analgesia, steroids and GI-risk management more safely.
Why long-term users should be reviewed after a major diagnosis change
New kidney, liver, GI or endocrine disease may alter the overall benefit-risk balance and justify a different pain strategy.
Why appetite trends belong in long-term monitoring
A gradual fall in appetite can be easy to miss in chronic treatment. Tracking meal interest alongside mobility helps identify whether the medicine is improving comfort without creating a new quality-of-life problem.
Last reviewed: October 2026. Educational information only; grapiprant should be used under veterinary direction as part of an individualized osteoarthritis plan.
